And this was an arbitrary 15% cap that was applied across the board rather than the negotiations that occur between NIH or other such scientific agencies and the grant recipient. So this came out of the blue. But I was shocked for another reason. In our appropriations bill, we had specific language that prevented the administration from changing the way indirect costs were applied and calculated and negotiated. So this should not have happened, which is why it is in court now. Having said that, we do need to have more transparency, more accountability, and work toward lowering the administrative burden, as your CEO has mentioned to me, of indirect costs. (15:36–15:54)
CLAIM
Asserts that the appropriations bill included language to prevent changes to indirect cost calculations.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
